14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CDRE vs COCH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDRE carries a Unified Composite Score of 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin).
Growth vs. Quality Trade-Off: CDRE earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. COCH 35.1/100 SELL) and 0.87β · 42% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both CDRE (39.6/100 SELL) and COCH (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CDRE vs COCH Key Questions & Quantitative Answers
As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDRE carries a Unified Composite Score of 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin). Growth vs. Quality Trade-Off: CDRE earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. COCH 35.1/100 SELL) and 0.87β · 42% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both CDRE (39.6/100 SELL) and COCH (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
CDRE leads the Growth & Scale pillar: CDRE posts +30.2% YoY revenue growth and +37.5% YoY earnings growth on $733M TTM revenue (42.8% gross margin, 12.5% operating margin), compared with COCH at +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), CDRE cumulative revenue shifted +52.5% while COCH shifted N/A. In operating R&D and SG&A reinvestment, CDRE deploys 30.3% of Rev ($222M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCH.
CDRE screens cheaper on headline valuation multiples. CDRE trades at 18.5x Forward P/E, 33.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (10.4% FCF margin), whereas COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDRE (11.6% ROE) versus COCH (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CDRE carries 47.3% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.87β · 42% Vol realized risk). By comparison, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.